Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Pneumocystis jiroveci pneumonia (PcP) increased in non HIV immunocompromised patients.
Mortality remains high for those patients with comorbidities (50% for patients with the most
severe Pneumocystis pneumonia). Physiopathology, characteristics and outcome of PcP in
non-HIV patients remains different from those in HIV patients. Steroids in HIV patients with
PcP has been associated with decreased mortality but in non-HIV patients, adjunctive steroids
remains controversy. Some retrospective studies in that field did not find any beneficial
effects of steroids ((1mg/kg/jour d'Equivalent Prednisone (EP)). However, all the studies
were retrospective, non randomised studies including various underlying disease and severity
of PcP was variable. Moreover, dosage and delay of steroids were variable leading difficult
to interpret all the results.
The investigators want to demonstrate the beneficial effect of steroid during PcP in non-HiV
immunocompromised patients with a double blinded randomised clinical trials comparing
adjunctive steroids to placebo.